Trials / Completed
CompletedNCT05890976
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Chinese Adults With Overweight or Obesity (OASIS 3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either get semaglutide or placebo once daily morning for 44 weeks. In addition to taking the medicine, participants will have talks with study staff about: * Healthy food choices * How to be more physically active * What participants can do to lose weight This study will last for about 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Participants will receive semaglutide tablets orally once daily for 44 weeks. |
| DRUG | Semaglutide Placebo | Participants will receive placebo matched to semaglutide. |
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2025-01-16
- Completion
- 2025-01-16
- First posted
- 2023-06-06
- Last updated
- 2026-01-22
Locations
16 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05890976. Inclusion in this directory is not an endorsement.